TY  - JOUR
AU  - Powles, Thomas
AU  - Park, Se Hoon
AU  - Voog, Eric
AU  - Caserta, Claudia
AU  - Valderrama, Begoña P
AU  - Gurney, Howard
AU  - Kalofonos, Haralabos
AU  - Radulovic, Sinisa
AU  - Demey, Wim
AU  - Ullén, Anders
AU  - Loriot, Yohann
AU  - Sridhar, Srikala S
AU  - Tsuchiya, Norihiko
AU  - Kopyltsov, Evgeny
AU  - Sternberg, Cora N
AU  - Bellmunt, Joaquim
AU  - Aragon-Ching, Jeanny B
AU  - Petrylak, Daniel P
AU  - Laliberte, Robert J
AU  - Huang, Bo
AU  - Costa, Nuno
AU  - Blake-Haskins, John A
AU  - Grivas, Petros
PY  - 2022
DO  - 10.2217/fon-2021-1631
UR  - http://hdl.handle.net/10668/20493
T2  - Future oncology (London, England)
AB  - This is a plain language summary of an article originally published in The New England Journal of Medicine. It is about initial results (collected in October 2019) from the JAVELIN Bladder 100 study (a clinical trial), which looked at avelumab...
LA  - en
KW  - JAVELIN Bladder 100
KW  - avelumab
KW  - bladder cancer
KW  - immunotherapy
KW  - lay summary
KW  - maintenance treatment
KW  - plain language summary
KW  - urothelial cancer
KW  - Antibodies, Monoclonal, Humanized
KW  - Carcinoma, Transitional Cell
KW  - Drug-Related Side Effects and Adverse Reactions
KW  - Humans
KW  - Language
KW  - Quality of Life
KW  - Urinary Bladder
KW  - Urinary Bladder Neoplasms
TI  - Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
TY  - research article
VL  - 18
ER  -